MDT vs NVS
MDT: Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain, restore health, and extend life across 150+ countries. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | MDT | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $85.39 | $156.11 | |
| Market cap as of 2026-08-03 | $109.3B | $232.1B | |
| P/E as of 2026-08-03 | 22.91 | 22.53 | NVS lower |
| PEG as of 2026-08-03 | 3.09 | 3.66 | MDT lower |
| Net margin as of 2026-08-03 | +13.2% | +22.5% | NVS higher |
| Gross margin as of 2026-08-03 | +65.3% | +75.0% | NVS higher |
| Operating margin as of 2026-08-03 | +17.8% | +29.9% | NVS higher |
| ROE as of 2026-08-03 | +9.8% | +29.9% | NVS higher |
| ROA as of 2026-08-03 | +5.2% | +11.1% | NVS higher |
| Debt / equity as of 2026-08-03 | 0.57 | 1.18 | MDT lower |
| Revenue growth (YoY) as of 2026-08-03 | +8.4% | +3.3% | MDT higher |
| Revenue CAGR (3y) SEC XBRL | +5.2% | n/a | |
| Dividend yield as of 2026-08-03 | +3.4% | +2.9% | MDT higher |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | 0.36 | 1.17 | |
| 1-year return as of 2026-07-31 close | -5.4% | +32.6% | NVS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.